Depression - Pipeline Review, H1 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Depression - Pipeline Review, H1 2019
Summary
The latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 16, 34, 36, 2, 78, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.
Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
The latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 16, 34, 36, 2, 78, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.
Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development for Depression, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Adamed Sp zoo, H1 2019
Depression - Pipeline by Addex Therapeutics Ltd, H1 2019
Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Alkermes Plc, H1 2019
Depression - Pipeline by Allergan Plc, H1 2019
Depression - Pipeline by Amorsa Therapeutics Inc, H1 2019
Depression - Pipeline by Anavex Life Sciences Corp, H1 2019
Depression - Pipeline by Angelini Group, H1 2019
Depression - Pipeline by Atai Life Sciences AG, H1 2019
Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Axsome Therapeutics Inc, H1 2019
Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Bionomics Ltd, H1 2019
Depression - Pipeline by BioXcel Therapeutics Inc, H1 2019
Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2019
Depression - Pipeline by Bristol-Myers Squibb Co, H1 2019
Depression - Pipeline by Calico LLC, H1 2019
Depression - Pipeline by Celgene Corp, H1 2019
Depression - Pipeline by Cellix Bio Pvt Ltd, H1 2019
Depression - Pipeline by Celon Pharma SA, H1 2019
Depression - Pipeline by Cerecor Inc, H1 2019
Depression - Pipeline by Clera Inc, H1 2019
Depression - Pipeline by Clexio Biosciences Ltd, H1 2019
Depression - Pipeline by Delpor Inc, H1 2019
Depression - Pipeline by Denovo Biopharma LLC, H1 2019
Depression - Pipeline by Douglas Pharmaceuticals Ltd, H1 2019
Depression - Pipeline by Eisai Co Ltd, H1 2019
Depression - Pipeline by Eli Lilly and Co, H1 2019
Depression - Dormant Projects, H1 2019
Depression - Discontinued Products, H1 2019
List Of Figures
Number of Products under Development for Depression, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
RELATED REPORTS
Treatment Resistant Depression (Central Nervous System) - Drugs in Development, 2021
Treatment Resistant Depression (Central Nervous System) - Drugs in Development, 2021Treatment Resistant Depression (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Treatment Resistant Depression pipeline
View ReportRespiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021
Respiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021Respiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021 provides an overview of the Respiratory Depression (Hypoventilation) pipeline landscape.The report provides comprehensive
View ReportNatural Killer Cell Therapies - Pipeline Insight, 2021
DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the
View ReportBinge-eating disorder - Pipeline Insight, 2021
DelveInsights, Binge-eating disorder - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
